I hope you are right Enrico because Marsden said very straight in the ShareSoc broadcast that a successful vaccine could completely undermine his forecasts for 2021. If he is still selling 100,000 treatments a month for 2021 and 2022 I will be over the moon. And financially very secure.
Sharedealer, indeed I have often noticed the strange coincidence of sales tending to involve both a seller and a buyer. What surprised was a) the price itself, b) that such a relatively high price was recorded as a sale, and c) that it was registered at 07.28 with today's date. I assume a late report from yesterday would carry yesterday's date
Manifesto, I started topping up as soon as RM mentioned going to shareholders in his last video. I did not think it would be offered to PIs. Final top up last week at 191 after the RNS. It is only about 10% above the price we can buy at in the offer. Just thought I would get on with it. Fingers still crossed for next 12 months.
pmjh, Aurélien Mary MD, at CHU Aliens has a trial of interferon beta 1b listed on clinical trials.gov - Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study. The last update was, I think, 20th July. Is this the guy who tweeted about French approval for SNG001 as of 15th?. Even if his trial is beta 1b he must know what's going on?
The agenda is available on line if you google - EMA meeting 15 October 2020. I did a search but found no reference to Synairgen or SNG001. The only interferon on the list is from Biogen Netherlands. Does not necessarily mean SNG is not being discussed; there is a note that, for commercial confidentiality reasons, not all agenda information is published.